AU2018371010C1 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds - Google Patents
Sulfone pyridine alkyl amide-substituted heteroaryl compounds Download PDFInfo
- Publication number
- AU2018371010C1 AU2018371010C1 AU2018371010A AU2018371010A AU2018371010C1 AU 2018371010 C1 AU2018371010 C1 AU 2018371010C1 AU 2018371010 A AU2018371010 A AU 2018371010A AU 2018371010 A AU2018371010 A AU 2018371010A AU 2018371010 C1 AU2018371010 C1 AU 2018371010C1
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- amino
- carboxamide
- methanesulfonylpyridin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022228101A AU2022228101B2 (en) | 2017-11-21 | 2022-09-06 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| AU2023255024A AU2023255024B2 (en) | 2017-11-21 | 2023-10-27 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589165P | 2017-11-21 | 2017-11-21 | |
| US62/589,165 | 2017-11-21 | ||
| PCT/US2018/061726 WO2019103952A1 (en) | 2017-11-21 | 2018-11-19 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022228101A Division AU2022228101B2 (en) | 2017-11-21 | 2022-09-06 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2018371010A1 AU2018371010A1 (en) | 2020-07-02 |
| AU2018371010B2 AU2018371010B2 (en) | 2022-06-09 |
| AU2018371010C1 true AU2018371010C1 (en) | 2024-09-26 |
Family
ID=65036887
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018371010A Active AU2018371010C1 (en) | 2017-11-21 | 2018-11-19 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| AU2022228101A Active AU2022228101B2 (en) | 2017-11-21 | 2022-09-06 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| AU2023255024A Active AU2023255024B2 (en) | 2017-11-21 | 2023-10-27 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022228101A Active AU2022228101B2 (en) | 2017-11-21 | 2022-09-06 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| AU2023255024A Active AU2023255024B2 (en) | 2017-11-21 | 2023-10-27 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11021462B2 (enExample) |
| EP (1) | EP3713930A1 (enExample) |
| JP (2) | JP7258903B2 (enExample) |
| KR (1) | KR102702228B1 (enExample) |
| CN (1) | CN111315737B (enExample) |
| AR (1) | AR113895A1 (enExample) |
| AU (3) | AU2018371010C1 (enExample) |
| BR (1) | BR112020009606A2 (enExample) |
| CA (1) | CA3083122A1 (enExample) |
| CL (1) | CL2020001338A1 (enExample) |
| CO (1) | CO2020006139A2 (enExample) |
| EA (1) | EA202091269A1 (enExample) |
| IL (1) | IL274816B2 (enExample) |
| MX (1) | MX2020005210A (enExample) |
| MY (1) | MY202167A (enExample) |
| PE (1) | PE20211461A1 (enExample) |
| SG (1) | SG11202004592TA (enExample) |
| TW (1) | TWI776994B (enExample) |
| WO (1) | WO2019103952A1 (enExample) |
| ZA (1) | ZA202003717B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7258903B2 (ja) * | 2017-11-21 | 2023-04-17 | ブリストル－マイヤーズ スクイブ カンパニー | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| EP4007757B1 (en) | 2019-08-01 | 2025-09-10 | Sperogenix Therapeutics Limited | Heterocyclic compounds as kinase inhibitor and uses thereof |
| CN115160297B (zh) * | 2020-12-22 | 2023-03-31 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| JP2024510274A (ja) | 2021-03-16 | 2024-03-06 | アンルイ バイオメディカル テクノロジー （グァンヂョウ） カンパニー リミテッド | アミノヘテロアリール化合物および組成物 |
| US20240182429A1 (en) * | 2021-03-30 | 2024-06-06 | Zhejiang Wenda Pharma Technology Ltd. | Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use |
| US20250066322A1 (en) * | 2021-05-14 | 2025-02-27 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| CN115466289A (zh) * | 2021-06-11 | 2022-12-13 | 爱科诺生物医药(香港)有限公司 | 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用 |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| TW202339749A (zh) | 2021-12-16 | 2023-10-16 | 大陸商凌科藥業有限公司 | Ｔｙｋ２抑制劑及其組合物和方法 |
| CN116693449A (zh) * | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| CN117257752A (zh) * | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 药物组合物及其用途 |
| CN120303268A (zh) * | 2022-12-16 | 2025-07-11 | 津药生物科技（天津）有限公司 | 新型含杂环取代的丙烯酸衍生物及其用途 |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130178478A1 (en) * | 2012-01-10 | 2013-07-11 | Hoffman-La Roche Inc. | Pyridazine amide compounds |
| WO2014074661A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
| WO2015069310A1 (en) * | 2013-11-07 | 2015-05-14 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1211024A1 (en) * | 2012-10-19 | 2016-05-13 | 霍夫曼-拉罗奇有限公司 | Inhibitors of syk |
| BR112015010244A8 (pt) * | 2012-11-08 | 2019-10-01 | Bristol Myers Squibb Co | compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso |
| MX375752B (es) * | 2013-12-05 | 2025-03-06 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton. |
| MA48602A (fr) | 2016-12-13 | 2020-03-18 | Bristol Myers Squibb Co | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha |
| JP7258903B2 (ja) * | 2017-11-21 | 2023-04-17 | ブリストル－マイヤーズ スクイブ カンパニー | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 |
-
2018
- 2018-11-19 JP JP2020545054A patent/JP7258903B2/ja active Active
- 2018-11-19 CA CA3083122A patent/CA3083122A1/en active Pending
- 2018-11-19 SG SG11202004592TA patent/SG11202004592TA/en unknown
- 2018-11-19 CN CN201880072389.7A patent/CN111315737B/zh active Active
- 2018-11-19 WO PCT/US2018/061726 patent/WO2019103952A1/en not_active Ceased
- 2018-11-19 BR BR112020009606-7A patent/BR112020009606A2/pt unknown
- 2018-11-19 KR KR1020207017459A patent/KR102702228B1/ko active Active
- 2018-11-19 EA EA202091269A patent/EA202091269A1/ru unknown
- 2018-11-19 MX MX2020005210A patent/MX2020005210A/es unknown
- 2018-11-19 MY MYPI2020002150A patent/MY202167A/en unknown
- 2018-11-19 PE PE2020000703A patent/PE20211461A1/es unknown
- 2018-11-19 AU AU2018371010A patent/AU2018371010C1/en active Active
- 2018-11-19 IL IL274816A patent/IL274816B2/en unknown
- 2018-11-19 EP EP18836556.3A patent/EP3713930A1/en active Pending
- 2018-11-20 AR ARP180103395A patent/AR113895A1/es unknown
- 2018-11-20 US US16/195,951 patent/US11021462B2/en active Active
- 2018-11-20 TW TW107141159A patent/TWI776994B/zh active
-
2020
- 2020-05-19 CO CONC2020/0006139A patent/CO2020006139A2/es unknown
- 2020-05-20 CL CL2020001338A patent/CL2020001338A1/es unknown
- 2020-06-19 ZA ZA2020/03717A patent/ZA202003717B/en unknown
-
2021
- 2021-04-28 US US17/242,428 patent/US11787779B2/en active Active
-
2022
- 2022-09-06 AU AU2022228101A patent/AU2022228101B2/en active Active
-
2023
- 2023-04-05 JP JP2023061359A patent/JP7490107B2/ja active Active
- 2023-09-05 US US18/461,093 patent/US12365667B2/en active Active
- 2023-10-27 AU AU2023255024A patent/AU2023255024B2/en active Active
-
2025
- 2025-06-11 US US19/234,470 patent/US20250304555A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130178478A1 (en) * | 2012-01-10 | 2013-07-11 | Hoffman-La Roche Inc. | Pyridazine amide compounds |
| WO2014074661A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
| WO2015069310A1 (en) * | 2013-11-07 | 2015-05-14 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023255024B2 (en) | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | |
| US11597721B2 (en) | Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFNα responses | |
| US10273237B2 (en) | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | |
| EP4143180A1 (en) | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators | |
| EP3917912B1 (en) | Amide-disubstituted pyridine or pyridazine compounds | |
| US12473290B2 (en) | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | |
| EA041710B1 (ru) | Сульфон-, пиридин-, алкил-, амидзамещенные гетероарильные соединения | |
| EA046543B1 (ru) | Амидзамещенные гетероциклические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAY 2024 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAY 2024 |